Recent blog posts
CLDN24 Biologics Sequence Review Report 2026: Claudin-24 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN24 Biologics Sequence Review Report 2026: Claudin-24 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN24 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN23 Biologics Sequence Review Report 2026: Claudin-23 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN23 Biologics Sequence Review Report 2026: Claudin-23 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN22 Biologics Sequence Review Report 2026: Claudin-22 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN22 Biologics Sequence Review Report 2026: Claudin-22 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN22 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN19 Biologics Sequence Review Report 2026: Claudin-19 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN19 Biologics Sequence Review Report 2026: Claudin-19 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN19 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN20 Biologics Sequence Review Report 2026: Claudin-20 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN20 Biologics Sequence Review Report 2026: Claudin-20 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN16 Biologics Sequence Review Report 2026: Claudin-16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN16 Biologics Sequence Review Report 2026: Claudin-16 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN14 Biologics Sequence Review Report 2026: Claudin-14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN14 Biologics Sequence Review Report 2026: Claudin-14 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN15 Biologics Sequence Review Report 2026: Claudin-15 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN15 Biologics Sequence Review Report 2026: Claudin-15 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN11 Biologics Sequence Review Report 2026: Claudin-11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN11 Biologics Sequence Review Report 2026: Claudin-11 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN10 Biologics Sequence Review Report 2026: Claudin-10 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN10 Biologics Sequence Review Report 2026: Claudin-10 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →